A study of three immunotherapy drugs for advanced melanoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of three immunotherapy drugs (fianlimab, cemiplimab, and ipilimumab) for people with advanced melanoma that has stopped responding to previous PD-1/PD-L1 treatment. It aims to see if this new combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your melanoma must be advanced (stage III or IV) and cannot be surgically removed, or it has spread to other parts of the body.
- You must have already received treatment with a PD-1/PD-L1 immunotherapy drug, and your cancer grew or came back on that treatment.
- You need to be able to get a biopsy or have a stored tumor sample from a previous biopsy.
- Your overall health should be good enough to carry out daily activities (ECOG score 0 or 1).
- You must have at least one tumor that can be measured on scans.
- You cannot have certain types of melanoma, like uveal melanoma, or untreated brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (IMC-F106C) combined with standard treatments against the usual nivolumab-based therapy for people with advanced melanoma who have not been treated before. It's for people who carry a specific immune system marker (HLA-A*02:01) and are in fairly good health.
This trial tests a new combination of two immunotherapy drugs plus a targeted therapy (bevacizumab) for people with advanced melanoma whose cancer continued to grow after previous immunotherapy. The goal is to see if this combination can help control the cancer.
This trial tests a new drug (iSCIB1+) combined with two standard immunotherapy drugs (ipilimumab and nivolumab) as the first treatment for advanced melanoma that cannot be removed by surgery. The goal is to see if adding iSCIB1+ helps the immune system fight the cancer better.
This trial tests a new drug, OPM-101, combined with an immunotherapy drug (anti-PD-1) for people with advanced melanoma that has stopped responding to anti-PD-1 treatment. The goal is to see if this combination can help control the cancer.
This trial tests whether giving two immunotherapy drugs before surgery can help shrink melanoma and improve outcomes. The drugs are given to boost your immune system to attack the cancer before it's removed.
This trial tests a combination of daily low-dose cyclophosphamide (a chemotherapy pill) and pembrolizumab (an immunotherapy) in people with advanced melanoma that has stopped responding to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
Hear when a new Advanced Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.